Genetic variants cause 10% resistance to Ozempic
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Genetic variants linked to GLP‑1 resistance are present in roughly 10% of the population, per the Stanford‑led study.
- Clinical trial data show carriers of these variants are significantly less likely to reach target blood‑glucose levels after six months of GLP‑1 therapy.
- Researchers conducted human and mouse experiments and analyzed a decade of trial data, publishing the results in Genome Medicine.
- Anna Gloyn said early identification of responders would help patients reach effective therapy sooner and move diabetes care toward precision medicine.
- Weight‑loss outcomes remained inconclusive, with the study calling for further investigation into how the variants affect obesity treatment with GLP‑1 drugs.
Why it matters: Patients with the GLP‑1‑resistant variants—about one in ten—will likely need alternative diabetes regimens, while clinicians can use genetic testing to avoid ineffective Ozempic prescriptions, reducing trial‑and‑error costs.
